Last reviewed · How we verify
MT-6548
MT-6548 is a selective androgen receptor modulator (SARM) that activates androgen signaling in muscle and bone while minimizing effects on prostate and other androgen-sensitive tissues.
MT-6548 is a selective androgen receptor modulator (SARM) that activates androgen signaling in muscle and bone while minimizing effects on prostate and other androgen-sensitive tissues. Used for Muscle wasting / sarcopenia, Bone health / osteoporosis.
At a glance
| Generic name | MT-6548 |
|---|---|
| Also known as | vadadustat, AKB-6548 |
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Selective Androgen Receptor Modulator (SARM) |
| Target | Androgen Receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Musculoskeletal / Endocrinology |
| Phase | Phase 3 |
Mechanism of action
SARMs like MT-6548 bind to the androgen receptor with tissue selectivity, promoting anabolic effects in skeletal muscle and bone through differential coactivator recruitment. This selectivity aims to provide the benefits of androgens for muscle wasting and bone health without the unwanted androgenic side effects associated with traditional androgens or testosterone replacement therapy.
Approved indications
- Muscle wasting / sarcopenia
- Bone health / osteoporosis
Common side effects
- Headache
- Nausea
- Fatigue
Key clinical trials
- Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
- Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
- Effects of Iron Supplements on the Pharmacokinetics of MT-6548 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT-6548 CI brief — competitive landscape report
- MT-6548 updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI